Physicians’ Opinions Survey on FDA’s Bydureon Approval

2012-03-06
Published : Mar-2012

Physicians were asked to assess their impressions of Bydureon in terms of efficacy, safety, tolerability, expected use, and other important factors. Key questions are broken down by specialty or familiarity to highlight difference in physician perceptions

Highlights

Datamonitor anticipates that the initial enthusiasm will ultimately be muted once physicians gain experience with the drug. Nevertheless, a once-weekly antidiabetic agent clearly represents an attractive option for type 2 diabetes patients, and physicians expect the drug to be a welcome addition to their armamentarium.

FDA’s Bydureon Approval

Published: February 2012
Price
: Single User License US$3800            Corporate User License – US$9500

                    Request Sample


Your key questions answered
  • Assess physicians’ opinions of Bydureon as compared with Amylin’s twice-daily Byetta (exenatide) and Novo Nordisk’s once-daily Victoza (liraglutide)
  • Determine physicians’ expectations for Bydureon’s uptake, line of therapy, and use in combination with other antidiabetics
  • Evaluate how Bydureon may expand the overall market for GLP-1 agonists

Table of Contents

BYDUREON FDA APPROVAL: PHYSICIAN OPINION
Background

SURVEY RESULTS
Demographics
Limited familiarity with PCPs could present a marketing challenge
Impressions of Bydureon’s efficacy differ based on familiarity
Tolerability issues trump safety concerns among physicians familiar with Bydureon
High expectations for Bydureon use will likely come down with increased experience
Endocrinologists expect to use Bydureon in earlier line of therapy compared to PCPs
Combination use with oral antidiabetics is likely
Physicians expect Bydureon to expand the GLP-1 agonist market
Conclusion

APPENDIX
Report methodology
Datamonitor consulting

Disclaimer

List of Figures

Figure: On average, how many patients with type 2 diabetes do you treat per month?
Figure: How familiar are you with Bydureon (once-weekly exenatide)?
Figure: For each attribute below, please select the one drug that you would prefer to prescribe, based on performance (or predicted performance) on that attribute
Figure: Please select the one drug that you would prefer to prescribe, based on efficacy (HbA1c lowering ability)
Figure: Please rank the following potential safety (and tolerability) issues you are most concerned about with Bydureon on a scale of 1 to 7, where 1 is the issue of greatest concern and 7 is the issue of least concern
Figure: Please select the one drug that you would prefer to prescribe, based on injection device
Figure: Where in the treatment algorithm do you think you will most commonly prescribe Bydureon?
Figure: Please consider your hypothetical Bydureon-treated patient population a year post-launch. What percentage of the Bydureon-treated patient population do you expect to have previously been treated with each of the following options?
Figure: Please choose up to three drug classes with which Bydureon could be used in combination. If there are more than three classes, please select the three most likely
Figure: Please give your opinion on how the introduction of Bydureon, and any other market trends, will impact on the number of patients on GLP-1 agonists in the US

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
More Reports
Title Price Buy Now

Auto-Immune Diseases Diagnostic Tests – Medical Devices Pipeline Assessment, 2018

Auto-Immune Diseases Diagnostic Tests - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Auto-Immune Diseases Diagnostic Tests - Medical Devices Pipeline Assessment, 2018" provides an overview of Auto-Immune Diseases Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Auto-Immune Diseases Diagnostic Tests pipeline products. This report is prepared using......
$4000

Transdermal Drug Delivery – Medical Devices Pipeline Assessment, 2018

Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2018" provides an overview of Transdermal Drug Delivery currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transdermal Drug Delivery pipeline products. This report is prepared using data sourced from in-house databases, secondary......
$4000

The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area

The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area Summary GlobalData's "The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area", provides an insight-rich overview of the key events and trends that our analysts expect to occur during 2018. This forward-looking view of the industry identifies key events that will occur across the major therapeutic areas - oncology, immunology, neurology, cardiovascular diseases, metabolic disorders, infectious diseases, and ophthalmology - and provides analyst insight on the potential ramifications of each event. 2018 promises to be a year of continued innovation in the biopharmaceutical industry across therapy areas. In this report, GlobalData's analysts highlight a selectio......
$500

Acne Vulgaris – Epidemiology Forecast to 2026

Acne Vulgaris - Epidemiology Forecast to 2026 Summary Acne vulgaris (acne) is a chronic inflammatory skin disease that presents as open or closed comedones and inflammatory lesions. Comedones include blackheads and whiteheads, while inflammatory lesions include papules, pustules, or cysts. Acne is a common skin disease that predominantly affects adolescents and young adults, but can also persist into adulthood. Mortality is not associated with acne, although major physical and psychological characteristics may develop, such as acne scarring, poor self-esteem, depression, and anxiety. The distribution of acne in the population is influenced by genetic background and dietary habits. For age- and sex-specific total prevalent cases, GlobalData epidemiologists utilized country-specific data ......
$3995

Dental Biomaterials – Medical Devices Pipeline Assessment, 2018

Dental Biomaterials - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Dental Biomaterials - Medical Devices Pipeline Assessment, 2018" provides an overview of Dental Biomaterials currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dental Biomaterials pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by......
$4000

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Jordan

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Jordan Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Jordan". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Jordan. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Jordan. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical market. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData's......
$1995

PharmSource: Demand and Supply for Contract Manufacturing of Injectable Drugs Through 2023

PharmSource: Demand and Supply for Contract Manufacturing of Injectable Drugs Through 2023 Summary This report is the 6th edition of our long-running analysis of the injectables CMO industry. It provides an expert quantitative analysis on the latest trends and plans for outsourcing commercially approved injectable products. It combines the rich data resources of PharmSource and the GlobalData Pharmaceutical Intelligence Center with our 20 years' experience in analyzing the injectables CMO industry to provide the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm. Scope - The report is based on the most recent data on industry capacity, the injectables pipeline and the behaviors of the key biopharmaceutical industry actors. - Th......
$4995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Denmark

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Denmark Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Denmark". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Denmark. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis......
$1995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Sweden

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Sweden Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Sweden". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Sweden. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Sweden. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house anal......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for December 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in December 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the re......
$1000